Pyxis Oncology updates patient enrollment for Phase 1 trial of micvotabart pelidotin

Published 04/08/2025, 12:34
Pyxis Oncology updates patient enrollment for Phase 1 trial of micvotabart pelidotin

Pyxis Oncology , Inc. (NASDAQ:PYXS), a clinical-stage biotech company with a market capitalization of $68 million and strong liquidity position, announced Monday that revisions to patient enrollment for its Phase 1 monotherapy clinical trial of micvotabart pelidotin (MICVO), formerly known as PYX-201, were posted on ClinicalTrials.gov on July 31. According to InvestingPro data, the company maintains more cash than debt on its balance sheet, though it’s currently experiencing rapid cash burn. The trial is a first-in-human, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of MICVO in participants with advanced solid tumors. The study includes a dose escalation phase and a dose expansion phase (NCT05720117).

According to the company’s statement, the revision reflects the maximum number of patients permitted to enroll in the trial according to the study protocol. Pyxis Oncology confirmed that its previous guidance regarding the estimated number of head and neck squamous cell carcinoma patients to be included in the dose expansion phase remains unchanged, as previously disclosed in its quarterly report filed with the Securities and Exchange Commission on May 15.

Pyxis Oncology’s common stock is listed on the Nasdaq Global Select Market under the ticker symbol PYXS. This information is based on a press release statement included in the company’s filing with the Securities and Exchange Commission.

In other recent news, Pyxis Oncology, Inc. announced the retirement of Pamela Connealy from her positions as Chief Financial Officer and Chief Operating Officer. The company clarified that her retirement was not due to any disagreements with auditors or management over accounting or financial disclosures. Connealy will receive severance benefits as per her employment agreement, contingent upon signing the company’s separation and release agreement. Additionally, Pyxis Oncology held its Annual Meeting of Stockholders, where three Class I directors were elected to serve until the 2028 Annual Meeting. Dr. Santhosh Palani, Mr. Darren Cline, and Dr. Rachel Humphrey were elected with varying levels of shareholder support. These developments reflect ongoing changes in Pyxis Oncology’s leadership and governance structure.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.